Abstract
Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubuleassociated protein tau in the central nervous system. In these disorders, tau is believed to cause neurodegeneration and neuronal loss due to the loss of function of the normal protein, and/or the gain of toxic properties by generating multimeric species. The obstacles found in amyloid-based therapies in Alzheimers disease, the most common tauopathy, have stimulated the search for alternative targets, including tau. In this article, we review the strategies aimed at reducing tau phosphorylation and aggregation as a target for drug intervention in tauopathies.
Keywords: Tau, tauopathies, Alzheimer, frontotemporal dementia, kinase inhibitors, dementia, immunization, Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, corticobasal syndrome, frontotemporal lobar degeneration, FTLD, post-encephalitic parkinsonism, Down syndrome, chronic traumatic encephalopathy, Niemann-Pick disease type C, postencephalitic parkinsonism, phosphorylation, glycation, glycosylation, ubiquitination, sumoylation, polyamination, nitration, nitrosylation, truncation, multiphoton microscopy, alsterpaullone, SB216763, tau fibrillization, phenothiazines, porphyrins, polyphenols, anthraquinones, phenyl thiazolylhydrazide benzofuran, pyrimidotriazines, quinoxaline, aminothienopyridazines, chloroquine, NAPVSIPQ, SMaRT technology, MMSE, AZD1080
CNS & Neurological Disorders - Drug Targets
Title: Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies
Volume: 9 Issue: 6
Author(s): Nahuai Badiola, Marc Suarez-Calvet and Alberto Lleo
Affiliation:
Keywords: Tau, tauopathies, Alzheimer, frontotemporal dementia, kinase inhibitors, dementia, immunization, Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, corticobasal syndrome, frontotemporal lobar degeneration, FTLD, post-encephalitic parkinsonism, Down syndrome, chronic traumatic encephalopathy, Niemann-Pick disease type C, postencephalitic parkinsonism, phosphorylation, glycation, glycosylation, ubiquitination, sumoylation, polyamination, nitration, nitrosylation, truncation, multiphoton microscopy, alsterpaullone, SB216763, tau fibrillization, phenothiazines, porphyrins, polyphenols, anthraquinones, phenyl thiazolylhydrazide benzofuran, pyrimidotriazines, quinoxaline, aminothienopyridazines, chloroquine, NAPVSIPQ, SMaRT technology, MMSE, AZD1080
Abstract: Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubuleassociated protein tau in the central nervous system. In these disorders, tau is believed to cause neurodegeneration and neuronal loss due to the loss of function of the normal protein, and/or the gain of toxic properties by generating multimeric species. The obstacles found in amyloid-based therapies in Alzheimers disease, the most common tauopathy, have stimulated the search for alternative targets, including tau. In this article, we review the strategies aimed at reducing tau phosphorylation and aggregation as a target for drug intervention in tauopathies.
Export Options
About this article
Cite this article as:
Badiola Nahuai, Suarez-Calvet Marc and Lleo Alberto, Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237403
DOI https://dx.doi.org/10.2174/187152710793237403 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The HIV Pandemic: A Forgotten Crisis?
Current Drug Targets - Infectious Disorders Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Glutamate and Schizophrenia
Current Neuropharmacology The Protective Role of Heme Oxygenase-1 in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Subject index to volume 1
Current HIV Research Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Design, Synthesis, Characterization, Molecular Docking, ADME Properties and <i>In Vivo</i> Antipsychotic Activity of Aripiprazole Related Drugs Candidates
Letters in Drug Design & Discovery Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Current Alzheimer Research Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets VDAC-Targeted Drugs Affecting Cytoprotection and Mitochondrial Physiology in Cerebrovascular and Cardiovascular Diseases
Current Medicinal Chemistry The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation
Current Alzheimer Research Recent Developments in Tau-Based Therapeutics for Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Lifestyle Modifications in the Treatment of Hypertension
Current Hypertension Reviews Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Current Vascular Pharmacology